214 related articles for article (PubMed ID: 34949934)
1. Ixekizumab for Psoriatic Arthritis: Safety, Efficacy, and Patient Selection.
Miller J; Puravath AP; Orbai AM
J Inflamm Res; 2021; 14():6975-6991. PubMed ID: 34949934
[TBL] [Abstract][Full Text] [Related]
2. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1.
Mease PJ; van der Heijde D; Ritchlin CT; Okada M; Cuchacovich RS; Shuler CL; Lin CY; Braun DK; Lee CH; Gladman DD;
Ann Rheum Dis; 2017 Jan; 76(1):79-87. PubMed ID: 27553214
[TBL] [Abstract][Full Text] [Related]
3. Ixekizumab Demonstrates Consistent Efficacy Versus Adalimumab in Biologic Disease-Modifying Anti-rheumatic Drug-Naïve Psoriatic Arthritis Patients Regardless of Psoriasis Severity: 52-Week Post Hoc Results from SPIRIT-H2H.
Kristensen LE; Okada M; Tillett W; Leage SL; El Baou C; Sapin C; Bradley AJ; Meszaros G; Dutz JP; de Vlam K
Rheumatol Ther; 2022 Feb; 9(1):109-125. PubMed ID: 34709605
[TBL] [Abstract][Full Text] [Related]
4. The effect of ixekizumab on axial manifestations in patients with psoriatic arthritis from two phase III clinical trials: SPIRIT-P1 and SPIRIT-P2.
Deodhar A; Gladman D; Bolce R; Sandoval D; Park SY; Leage SL; Nash P; Poddubnyy D
Ther Adv Musculoskelet Dis; 2023; 15():1759720X231189005. PubMed ID: 37645684
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Ixekizumab Versus Adalimumab in Biologic-naïve Patients With Active Psoriatic Arthritis and Moderate-to-severe Psoriasis: 52-week Results From the Randomized SPIRIT-H2H Trial.
Reich K; Kristensen LE; Smith SD; Rich P; Sapin C; Leage SL; McKenzie R; Schuster C; Riedl E; Gooderham M
Dermatol Pract Concept; 2022 May; 12(2):e2022104. PubMed ID: 35646453
[TBL] [Abstract][Full Text] [Related]
6. Ixekizumab treatment of biologic-naïve patients with active psoriatic arthritis: 3-year results from a phase III clinical trial (SPIRIT-P1).
Chandran V; van der Heijde D; Fleischmann RM; Lespessailles E; Helliwell PS; Kameda H; Burgos-Vargas R; Erickson JS; Rathmann SS; Sprabery AT; Birt JA; Shuler CL; Gallo G
Rheumatology (Oxford); 2020 Oct; 59(10):2774-2784. PubMed ID: 32031665
[TBL] [Abstract][Full Text] [Related]
7. Ixekizumab: an anti- IL-17A monoclonal antibody for the treatment of psoriatic arthritis.
Toussirot E
Expert Opin Biol Ther; 2018 Jan; 18(1):101-107. PubMed ID: 29187009
[TBL] [Abstract][Full Text] [Related]
8. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.
Rodgers M; Epstein D; Bojke L; Yang H; Craig D; Fonseca T; Myers L; Bruce I; Chalmers R; Bujkiewicz S; Lai M; Cooper N; Abrams K; Spiegelhalter D; Sutton A; Sculpher M; Woolacott N
Health Technol Assess; 2011 Feb; 15(10):i-xxi, 1-329. PubMed ID: 21333232
[TBL] [Abstract][Full Text] [Related]
9. Ixekizumab for treatment of adults with moderate-to-severe plaque psoriasis and psoriatic arthritis.
Vu TT; Gooderham M; Papp K
Expert Rev Clin Pharmacol; 2016 Nov; 9(11):1423-1433. PubMed ID: 27690669
[TBL] [Abstract][Full Text] [Related]
10. Ixekizumab Efficacy in Patients with Severe Peripheral Psoriatic Arthritis: A Post Hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (SPIRIT-P1).
Kameda H; Hagimori K; Morisaki Y; Holzkämper T; Konomi A; Dobashi H
Rheumatol Ther; 2023 Dec; 10(6):1683-1703. PubMed ID: 37858007
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1).
van der Heijde D; Gladman DD; Kishimoto M; Okada M; Rathmann SS; Moriarty SR; Shuler CL; Carlier H; Benichou O; Mease PJ
J Rheumatol; 2018 Mar; 45(3):367-377. PubMed ID: 29247148
[TBL] [Abstract][Full Text] [Related]
12. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial.
van der Heijde D; Cheng-Chung Wei J; Dougados M; Mease P; Deodhar A; Maksymowych WP; Van den Bosch F; Sieper J; Tomita T; Landewé R; Zhao F; Krishnan E; Adams DH; Pangallo B; Carlier H;
Lancet; 2018 Dec; 392(10163):2441-2451. PubMed ID: 30360964
[TBL] [Abstract][Full Text] [Related]
13. A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial.
Mease PJ; Smolen JS; Behrens F; Nash P; Liu Leage S; Li L; Tahir H; Gooderham M; Krishnan E; Liu-Seifert H; Emery P; Pillai SG; Helliwell PS;
Ann Rheum Dis; 2020 Jan; 79(1):123-131. PubMed ID: 31563894
[TBL] [Abstract][Full Text] [Related]
14. Ixekizumab for the treatment of psoriasis: an update on new data since first approval.
Blegvad C; Skov L; Zachariae C
Expert Rev Clin Immunol; 2019 Feb; 15(2):111-121. PubMed ID: 30589394
[No Abstract] [Full Text] [Related]
15. Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52.
Smolen JS; Mease P; Tahir H; Schulze-Koops H; de la Torre I; Li L; Hojnik M; Sapin C; Okada M; Caporali R; Gratacós J; Goupille P; Liu Leage S; Pillai S; Nash P
Ann Rheum Dis; 2020 Oct; 79(10):1310-1319. PubMed ID: 32660977
[TBL] [Abstract][Full Text] [Related]
16. Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials.
Genovese MC; Mysler E; Tomita T; Papp KA; Salvarani C; Schwartzman S; Gallo G; Patel H; Lisse JR; Kronbergs A; Leage SL; Adams DH; Xu W; Marzo-Ortega H; Lebwohl MG
Rheumatology (Oxford); 2020 Dec; 59(12):3834-3844. PubMed ID: 32449924
[TBL] [Abstract][Full Text] [Related]
17. Ixekizumab and complete resolution of enthesitis and dactylitis: integrated analysis of two phase 3 randomized trials in psoriatic arthritis.
Gladman DD; Orbai AM; Klitz U; Wei JC; Gallo G; Birt J; Rathmann S; Shrom D; Marzo-Ortega H
Arthritis Res Ther; 2019 Jan; 21(1):38. PubMed ID: 30696483
[TBL] [Abstract][Full Text] [Related]
18. Pregnancy outcomes in patients with psoriasis, psoriatic arthritis, or axial spondyloarthritis receiving ixekizumab.
Egeberg A; Iversen L; Kimball AB; Kelly S; Grace E; Patel H; Xu W; Gallo G; Riedl E; Feldman SR
J Dermatolog Treat; 2022 Aug; 33(5):2503-2509. PubMed ID: 34547967
[TBL] [Abstract][Full Text] [Related]
19. Measuring treatment effect on psoriatic arthritis-related domains: insights from the SPIRIT-H2H study at weeks 24 and 52.
Behrens F; Leage SL; Sapin C; Baou CE; De La Torre I; Meszaros G; Schett G; Combe B; van den Bosch F; Gossec L
Clin Rheumatol; 2021 Dec; 40(12):4943-4954. PubMed ID: 34515902
[TBL] [Abstract][Full Text] [Related]
20. Comparative efficacy and safety of targeted DMARDs for active psoriatic arthritis during induction therapy: A systematic review and network meta-analysis.
Lu C; Wallace BI; Waljee AK; Fu W; Zhang Q; Liu Y
Semin Arthritis Rheum; 2019 Dec; 49(3):381-388. PubMed ID: 31272807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]